Skip to content
OpenCapital
Get started

Vanda Pharmaceuticals VNDA Q4 2024 Annual earnings

Reported February 13, 2025 · After market close

Revenue$53.2MBeat by $935.0K
EPS-$0.08Beat by $0.06
Revenue estimate$52.3M
EPS estimate-$0.14

Next report

Jul 30, 2026 (Tomorrow)
Revenue estimate$61.9M
EPS estimate-$0.58

Versus estimates

Revenue

Q1 2026$51.7MMiss by $3.3MQ4 2025$57.2MMiss by $2.1MQ3 2025$56.3MMiss by $3.0MQ2 2025$52.6MMiss by $6.1MQ1 2025$50.0MBeat by $4.9M
Q4 2024$53.2MBeat by $935.0K

Diluted EPS

Q1 2026-$0.82Miss by $0.29Q4 2025-$0.46Beat by $1.72Q3 2025-$0.38Miss by $0.07Q2 2025-$0.46Miss by $0.12Q1 2025-$0.50Beat by $0.05
Q4 2024-$0.08Beat by $0.06

Ask the moment Vanda Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Vanda Pharmaceuticals report Q4 2024 earnings?
Vanda Pharmaceuticals (VNDA) reported Q4 2024 earnings on February 13, 2025 after market close.
What were Vanda Pharmaceuticals's Q4 2024 revenue and EPS?
Vanda Pharmaceuticals reported revenue of $53.2M and eps of $-0.08 for Q4 2024.
Did Vanda Pharmaceuticals beat estimates in Q4 2024?
Revenue beat the consensus estimate of $52.3M by $935.0K. EPS beat the consensus estimate of $-0.14 by $0.06.
Where can I find Vanda Pharmaceuticals's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001628280-25-005761) directly on SEC EDGAR. The filing index links above go to sec.gov.